Integrated Pharmacokinetics of Corydalis saxicola Alkaloids in MASH: Insights for Drug Disposition and Transporter Modulation

Study Background and Research Question

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe progression to metabolic dysfunction-associated steatohepatitis (MASH) represent a global health challenge, affecting nearly 38% of adults worldwide [source_type: paper][source_link: https://doi.org/10.1016/j.biopha.2025.118665]. These disorders are characterized by hepatic lipid accumulation, inflammation, and fibrosis, with complex interplay between metabolic, inflammatory, and fibrotic pathways. Traditional Chinese medicine-derived compounds, such as the total alkaloids from Corydalis saxicola Bunting (CSBTA), have shown therapeutic potential in attenuating MASLD/MASH progression. However, the pharmacokinetics (PK) and tissue distribution of CSBTA constituents—especially in the context of chronic liver disease—remain poorly understood. The reference study sought to address: How does the pathological state of MASH influence the PK properties and tissue distribution of CSBTA's main bioactive alkaloids, and what are the roles of metabolic enzymes and transporters in mediating these effects? [source_type: paper][source_link: https://doi.org/10.1016/j.biopha.2025.118665]

Key Innovation from the Reference Study

This work delivers an integrated, multi-level analysis of how MASH alters the systemic exposure, hepatic distribution, and intracellular accumulation of CSBTA's major alkaloids—dehydrocavidine, palmatine, and berberine. Going beyond standard PK profiling, the authors systematically investigate the contributions of cytochrome P450 enzymes (CYP450s), organic anion transporting polypeptide 1b2 (Oatp1b2), and P-glycoprotein (P-gp) to observed PK variability. Notably, the study links these molecular changes to pregnane X receptor (PXR) modulation, establishing a direct connection between disease state, transporter/enzyme expression, and alkaloid disposition [source_type: paper][source_link: https://doi.org/10.1016/j.biopha.2025.118665]. This integrative approach advances precision dosing and highlights the importance of transporter-mediated processes in chronic liver disease.

Methods and Experimental Design Insights

The researchers employed a combination of in vivo and in vitro models to dissect the PK and tissue distribution of CSBTA alkaloids:

• Animal models: Mice fed a normal chow diet (NCD) or a high-fat, high-cholesterol diet (HFHCD) to induce MASH pathology.
• Dosing regimens: Single and multiple intragastric administrations of CSBTA, followed by time-course sampling.
• Quantification: Ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) for plasma, tissue, and cellular concentrations of dehydrocavidine, palmatine, and berberine.
• Transport/metabolism assays: Use of transfected HEK293 and Caco-2 cell models for uptake/efflux studies, and liver microsome incubations to assess metabolic stability.
• Gene/protein expression: Quantitative PCR and Western blotting for CYP450s, Oatp1b2, P-gp, and PXR in hepatic tissues.

This multi-pronged design allowed the authors to correlate systemic PK changes with underlying transporter and enzyme modulation under pathological conditions [source_type: paper][source_link: https://doi.org/10.1016/j.biopha.2025.118665].

Protocol Parameters

• assay | UHPLC-MS/MS quantification | plasma/tissue/cell alkaloid levels | enables sensitive, specific measurement of PK profiles | paper
• assay | Caco-2/HEK293 transporter studies | efflux and uptake ratios | dissects transporter-specific contributions to disposition | paper
• assay | Liver microsome metabolism | metabolic clearance rate (μL/min/mg protein) | evaluates CYP450-mediated metabolism | paper
• assay | Multiple dosing (CSBTA) | daily, up to 7 days | models chronic exposure in disease state | paper
• assay | qPCR/Western blot | transporter/enzyme expression (relative units) | links molecular expression to PK outcomes | paper

Core Findings and Why They Matter

The study demonstrates several key points regarding the disposition of CSBTA alkaloids in MASH:

1. MASH pathology significantly increases systemic exposure and hepatic accumulation of dehydrocavidine, palmatine, and berberine compared to healthy mice. Multiple dosing further amplifies this effect, particularly for dehydrocavidine [source_type: paper][source_link: https://doi.org/10.1016/j.biopha.2025.118665].
2. Transporter and enzyme perturbations drive PK variability: MASH is associated with altered expression of CYP450s, downregulation of Oatp1b2 (involved in hepatic uptake), and reduced P-gp (critical for efflux). These changes collectively enhance intracellular and hepatic retention of the alkaloids [source_type: paper][source_link: https://doi.org/10.1016/j.biopha.2025.118665].
3. PXR modulation as a mechanistic link: The pregnane X receptor, a master regulator of drug metabolism and transport, is implicated in orchestrating the observed changes in transporter/enzyme expression during disease progression.
4. Clinical implication: The altered PK profile in MASH suggests that standard dosing regimens may lead to greater systemic and hepatic exposure, raising both therapeutic and safety considerations for MASLD/MASH patients.

These findings are critical for rationalizing dosing strategies in chronic liver disease and highlight the potential for transporter-targeted interventions to modulate drug disposition.

Comparison with Existing Internal Articles: The Transporter Perspective

While the reference study focuses on chronic liver disease and transporter-mediated variability in natural product pharmacokinetics, there are notable parallels with research in oncology and multidrug resistance (MDR). For example, several internal resources detail the use of Zosuquidar (LY335979) 3HCl as a selective P-glycoprotein (P-gp) inhibitor for overcoming MDR in cancer models:

• Zosuquidar (LY335979) 3HCl: Selective P-gp Inhibitor for MDR Reversal demonstrates how direct inhibition of P-gp restores drug sensitivity in P-gp overexpressing tumor cells, providing robust evidence for transporter-targeted therapy in acute myeloid leukemia (AML) and other cancers [source_type: workflow_recommendation][source_link: https://concanavalin-a.com/index.php?g=Wap&m=Article&a=detail&id=10804].
• Optimizing Multidrug Resistance Assays with Zosuquidar (LY335979) offers practical guidance for MDR assay design, highlighting the importance of workflow reproducibility and selective inhibitor choice [source_type: workflow_recommendation][source_link: https://biotin-hpdp.com/index.php?g=Wap&m=Article&a=detail&id=16095].

Both the liver disease and cancer literature converge on the centrality of P-gp and related transporters in determining drug disposition and efficacy. The reference study’s mechanistic findings on P-gp downregulation in MASH extend the importance of transporter biology beyond oncology, reinforcing the need for context-specific PK and transporter profiling in drug development.

Limitations and Transferability

Several limitations must be considered:

• The findings are based on mouse models with induced MASH, and while these recapitulate key aspects of human disease, there may be species-specific differences in transporter/enzyme expression and regulation.
• The study examines only three major CSBTA alkaloids; additional components or metabolites may exhibit distinct PK or interaction profiles.
• While in vitro transporter studies provide mechanistic insight, in vivo interactions within the complex hepatic environment may involve additional factors not fully captured in the models used.
• The relevance of PXR-driven modulation needs further validation in clinical MASLD/MASH cohorts.

Nonetheless, the integrative approach and transporter/enzyme focus provide a framework for future translational research in both TCM-derived and conventional therapeutics.

Research Support Resources

For researchers aiming to dissect the contributions of transporters like P-glycoprotein in disease models or to optimize multidrug resistance (MDR) assays—especially in the context of cancer or hepatic pharmacokinetics—high-purity tools such as Zosuquidar (LY335979) 3HCl (SKU A3956, APExBIO) can provide selective, validated inhibition of P-gp efflux activity. This is critical for both mechanistic transporter studies and workflow reliability in drug sensitivity assays. When designing experiments to probe transporter-mediated variability, validated inhibitors like Zosuquidar support rigorous dissection of MDR and facilitate translational insight [source_type: product_spec][source_link: https://www.apexbt.com/zosuquidar.html].